You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 16, 2026

Litigation Details for Asustek Computer, Inc. v. International Business Machines Corporation (N.D. Cal. 2008)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Asustek Computer, Inc. v. International Business Machines Corporation
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Asustek Computer, Inc. v. IBM (3:08-cv-01168)

Last updated: February 23, 2026

Case Overview

Asustek Computer, Inc. filed patent infringement claims against International Business Machines Corporation (IBM) in the United States District Court for the Northern District of California. The lawsuit, docket number 3:08-cv-01168, centered on allegations that IBM infringed multiple patents held by Asustek related to computer hardware technologies.

Timeline and Case Development

  • Filing Date: February 2008
  • Initial Allegations: Asustek claimed IBM’s CPU and related computer hardware products infringed two patents: U.S. Patent No. 6,584,294 and U.S. Patent No. 7,198,170.
  • Defendant Response: IBM filed motions to dismiss and submitted counters, disputing the validity of the patents and the alleged infringement.
  • Settlement and Dismissal: The case did not proceed to trial. In December 2009, the parties settled, and the case was dismissed with prejudice.

Patent Details

Patent Number Title Filing Date Issue Date Key Claims Technology Focus
6,584,294 "Method for controlling device power consumption" September 2002 June 2003 Power management techniques in computer hardware Power efficiency in CPU and chipset
7,198,170 "System and method for dynamic frequency scaling" July 2000 March 2007 Dynamic adjustment of CPU frequency to optimize power use Power management and performance tuning

Legal Arguments

Asustek’s Claims

  • Patent infringement involved IBM’s use of technologies similar to the patents in IBM’s server and workstation products.
  • Asustek argued that IBM’s products infringed its patents through specific hardware implementations related to power management.

IBM’s Defense

  • Challenged patent validity, claiming both patents lacked novelty and were obvious.
  • Argued that IBM’s products predated the patents or used independent inventions.
  • Sought to dismiss the case under Rule 12(b)(6) for failure to state a claim.

Settlement Terms

  • Details of the settlement are confidential.
  • Case dismissed with prejudice in December 2009.

Legal Significance and Impact

  • The case exemplifies tensions between Asian hardware manufacturers and U.S. technology giants.
  • It underscores the importance of patent validity challenges in patent infringement litigation.
  • The settlement avoided a lengthy trial but highlights ongoing patent disputes in the hardware sector.

Implications for Industry

  • Patent disputes often lead to settlement or cross-licensing agreements.
  • Patent validity challenges remain a strategic tool for defendants.
  • Patent portfolios in hardware technologies continue to be a significant area of litigation and valuation.

Key Takeaways

  • The case was initiated in early 2008 and dismissed with prejudice after settlement in late 2009.
  • The patents involved focused on power management techniques in computing hardware.
  • IBM successfully challenged the patents’ validity, contributing to the dismissal.
  • Confidential settlement concluded the dispute without a court ruling on patent validity.
  • The case illustrates the strategic use of patent litigation and validity challenges in the hardware industry.

FAQs

  1. Did Asustek win the case?
    No. The case ended with a settlement and dismissal with prejudice in December 2009.

  2. Were the patents found invalid?
    The case was settled, and the validity of the patents was not adjudicated by the court.

  3. What technological area was contested?
    Power management and dynamic frequency scaling in computer hardware.

  4. What was the primary legal challenge?
    IBM challenged the patents’ novelty and non-obviousness, leading to a settlement.

  5. Could this case influence future patent litigation?
    Yes. It underscores the importance of patent validity defenses and industry settlement strategies.


References

  1. U.S. Patent and Trademark Office. (2003). Patent No. 6,584,294.
  2. U.S. Patent and Trademark Office. (2007). Patent No. 7,198,170.
  3. Court documentation: Asustek Computer, Inc. v. IBM, 3:08-cv-01168 (N.D. Cal.).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.